46.82

2.65% +1.29

SpringWorks Therapeutics Inc (SWTX)

개요 뉴스 가격 이력 옵션 체인 토론 예측

전일 마감가:

$45.53

열려 있는:

$45.52

하루 거래량:

220.83K

시가총액:

$3.37B

수익:

순이익/손실:

$-325.10M

주가수익비율:

-9.614

EPS:

-4.87

순현금흐름:

$-230.18M

1주 성능:

+8.97%

1개월 성능:

-5.04%

6개월 성능:

+116.28%

1년 성능:

+99.91%

1일 변동 폭

$45.52

$47.25

52주 변동 폭

$18.00

$53.92

SpringWorks Therapeutics Inc Stock (SWTX) Company Profile

명칭

SpringWorks Therapeutics Inc

부문

Healthcare (1203)

산업

Biotechnology (688)

전화

203 883 9490

주소

100 Washington Boulevard, Stamford, CT

직원

트위터

@springworkstx

다음 수익 날짜

2024-05-16

최신 SEC 제출 서류

SWTX's Discussions on Twitter

SpringWorks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-02-05	개시	Guggenheim	Buy
2022-12-01	개시	BofA Securities	Buy
2021-01-19	재확인	H.C. Wainwright	Buy
2020-10-29	재확인	H.C. Wainwright	Buy
2020-05-05	개시	Barclays	Overweight
2020-03-19	업그레이드	H.C. Wainwright	Neutral → Buy
2020-03-04	다운그레이드	H.C. Wainwright	Buy → Neutral
2020-01-21	재확인	H.C. Wainwright	Buy
2019-12-04	개시	H.C. Wainwright	Buy
2019-10-08	개시	Cowen	Outperform
2019-10-08	개시	Goldman	Buy
2019-10-08	개시	JP Morgan	Overweight
2019-10-08	개시	Wedbush	Outperform

모두보기

SpringWorks Therapeutics Inc 주식(SWTX)의 최신 뉴스

SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire Inc.

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024

GlobeNewswire Inc.

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

GlobeNewswire Inc.

SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors

GlobeNewswire Inc.

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates

GlobeNewswire Inc.

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire Inc.

SpringWorks Therapeutics Inc (SWTX) 재무 분석

SpringWorks Therapeutics Inc (SWTX) 순이익 2024

SWTX은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -325.10M 달러로 보고했으며, 전년대비 -17.19% 감소했습니다.

SpringWorks Therapeutics Inc (SWTX) 현금흐름 2024

2023-12-31 종료 분기에 SWTX은 현금흐름(지난 12개월)으로 -230.18M 달러를 기록했으며, 전년 대비 -34.01% 감소했습니다.

SpringWorks Therapeutics Inc (SWTX) 주당 순이익 2024

SWTX이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -5.15달러이며, 전년 대비 +1.15% 성장했습니다.

SpringWorks Therapeutics Inc 주식 (SWTX) 내부자 거래

내부자 거래	관계	날짜	거래	비용	#주식	가치 ($)	#주식 총계
Pichl Daniel	Chief People Officer	Feb 16 '24	Sale	50.10	15,000	751,550	45,212
Ashar Bhavesh	Chief Commercial Officer	Feb 05 '24	Sale	49.32	4,834	238,435	58,154
Pichl Daniel	Chief People Officer	Feb 02 '24	Option Exercise	27.64	16,250	449,150	71,393
Pichl Daniel	Chief People Officer	Feb 02 '24	Sale	44.32	26,181	1,160,362	45,212
Ashar Bhavesh	Chief Commercial Officer	Feb 02 '24	Sale	44.37	3,222	142,976	62,988
Hambleton Julie	Director	Jul 19 '23	Sale	29.31	2,418	70,876	4,648
Hambleton Julie	Director	Jun 20 '23	Sale	26.92	2,400	64,603	7,066